Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib
Author:
Funder
University of Colorado
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference11 articles.
1. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial;Gettinger;Lancet Oncol,2016
2. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial;Kim;J Clin Oncol,2017
3. Brigatinib in crizotinib-refractory ALK+ non–small cell lung cancer: efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline brain lesion status [abstract];Huber;J Clin Oncol,2018
4. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer;Camidge;N Engl J Med,2018
5. Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC following treatment with crizotinib;Gemma;J Thorac Oncol,2019
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum;Clinical Lung Cancer;2024-01
2. Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer;Chest;2022-11
3. Early-Onset Pulmonary Events with Combined Brigatinib and Afatinib Treatment of L858/cisT790M/cisC797S NSCLC: A Case Report;American Journal of Case Reports;2022-08-22
4. The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation;International Journal of Molecular Sciences;2022-06-30
5. Modern treatment of ALK-positive non-small cell lung cancer;South Russian Journal of Cancer;2022-04-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3